This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Brainsway is happy to announce new coverage with Excellus BC/BS, effective immediately. This decision will now provide an additional 1.55 million patients in New York with access to the latest Deep TMS depression treatment.
We are equally pleased to announce that Blue Cross/ Blue Shield Mississippi has included coverage for Brainsway’s Deep TMS treatment as well. This new coverage will allow over 600,000 patients living in Mississippi to have access to Deep TMS to help beat their depression.